Nath Bio-Genes (India) Limited (NSE:NATHBIOGEN)
India · Delayed Price · Currency is INR 148.00
-2.92 (-1.93%)
Feb 13, 2026, 3:29 PM IST
Nath Bio-Genes (India) Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 |
Operating Revenue | 4,455 | 3,649 | 3,326 | 3,014 | 2,784 | 3,076 |
Other Revenue | 1.31 | 1.31 | 1.41 | - | - | -0 |
| 4,456 | 3,650 | 3,328 | 3,014 | 2,784 | 3,076 | |
Revenue Growth (YoY) | 25.13% | 9.70% | 10.42% | 8.26% | -9.49% | 9.89% |
Cost of Revenue | 1,281 | 902.49 | 903.04 | 814.33 | 936.65 | 980.14 |
Gross Profit | 3,175 | 2,748 | 2,425 | 2,199 | 1,847 | 2,095 |
Selling, General & Admin | 856.71 | 522.24 | 442.11 | 372.48 | 382.11 | 410.98 |
Other Operating Expenses | 1,823 | 1,716 | 1,482 | 1,338 | 1,088 | 1,013 |
Operating Expenses | 2,723 | 2,276 | 1,957 | 1,741 | 1,501 | 1,452 |
Operating Income | 452.63 | 471.49 | 467.6 | 458.79 | 345.7 | 643.36 |
Interest Expense | -121.77 | -99 | -86.29 | -95.73 | -101.25 | -79.02 |
Interest & Investment Income | 35.89 | 35.89 | 3.23 | 0.18 | 10.93 | 12.14 |
Currency Exchange Gain (Loss) | 6.4 | 6.4 | -0.14 | 4.3 | 0.59 | -1.23 |
Other Non Operating Income (Expenses) | 43.11 | -4.39 | -3.26 | -5.93 | -3.88 | -8.45 |
EBT Excluding Unusual Items | 416.26 | 410.38 | 381.15 | 361.59 | 252.08 | 566.79 |
Gain (Loss) on Sale of Assets | -10.35 | -10.35 | 0.01 | -0.01 | 0.04 | 0.04 |
Other Unusual Items | 52.9 | 5.4 | 34.49 | - | -887.82 | - |
Pretax Income | 459.21 | 405.84 | 415.65 | 361.64 | -634.34 | 567.51 |
Income Tax Expense | 28.01 | 19.85 | 19.46 | 11.53 | 39.52 | 10.9 |
Net Income | 431.2 | 386 | 396.19 | 350.11 | -673.85 | 556.62 |
Net Income to Common | 431.2 | 386 | 396.19 | 350.11 | -673.85 | 556.62 |
Net Income Growth | 12.77% | -2.57% | 13.16% | - | - | 10.26% |
Shares Outstanding (Basic) | 19 | 19 | 19 | 19 | 19 | 19 |
Shares Outstanding (Diluted) | 19 | 19 | 19 | 19 | 19 | 19 |
Shares Change (YoY) | -0.82% | - | - | - | - | - |
EPS (Basic) | 22.69 | 20.31 | 20.85 | 18.42 | -35.46 | 29.29 |
EPS (Diluted) | 22.69 | 20.31 | 20.85 | 18.42 | -35.46 | 29.29 |
EPS Growth | 13.70% | -2.57% | 13.16% | - | - | 10.26% |
Free Cash Flow | - | 96.61 | 478.18 | 354.85 | -39.56 | -104.34 |
Free Cash Flow Per Share | - | 5.08 | 25.16 | 18.67 | -2.08 | -5.49 |
Dividend Per Share | - | 2.000 | 2.000 | 2.000 | 2.000 | 2.000 |
Gross Margin | 71.26% | 75.28% | 72.86% | 72.98% | 66.35% | 68.13% |
Operating Margin | 10.16% | 12.92% | 14.05% | 15.22% | 12.42% | 20.92% |
Profit Margin | 9.68% | 10.57% | 11.91% | 11.62% | -24.21% | 18.10% |
Free Cash Flow Margin | - | 2.65% | 14.37% | 11.77% | -1.42% | -3.39% |
EBITDA | 494.37 | 509.32 | 500.21 | 488.91 | 376.54 | 671.52 |
EBITDA Margin | 11.09% | 13.95% | 15.03% | 16.22% | 13.53% | 21.83% |
D&A For EBITDA | 41.74 | 37.83 | 32.61 | 30.12 | 30.84 | 28.16 |
EBIT | 452.63 | 471.49 | 467.6 | 458.79 | 345.7 | 643.36 |
EBIT Margin | 10.16% | 12.92% | 14.05% | 15.22% | 12.42% | 20.92% |
Effective Tax Rate | 6.10% | 4.89% | 4.68% | 3.19% | - | 1.92% |
Revenue as Reported | 4,500 | 3,695 | 3,333 | 3,019 | 2,802 | 3,092 |
Advertising Expenses | - | 48.31 | 50.51 | 37.04 | 16.34 | 19.43 |
Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.